Yatiri Bio, Inc.

Yatiri Bio, Inc. has raised $1.2M in total funding. The most recent round was Series A.

Yatiri Bio, Inc. is headquartered in San Diego, CA.

Yatiri Bio, Inc. is re-enisioning the pharmaceutical industry's current drug discovery process by integrating patient data sets with testable empirical models to guide patient selection and clinical development, utilizing advanced proteomics and bioinformatics tools and deep learning models.

Drug discovery today relies mainly on genetic data, which the company says makes development slow and costly (over $3B and 12 years per drug with only a 5% clinical success rate).

Yatiri Bio builds proteomics and bioinformatics tools combined with deep learning models to identify disease-driving proteins and guide patient selection for clinical development.

Their stated angle is that proteins, not genes, are the true drivers of biology and disease, so they integrate patient proteomic data with testable empirical models to predict treatment response.

San Diego cancer-drug-discovery company co-founded in 2020 by Pilgrim Jackson (13 years at Celgene) and Afshin Mahmoudi; backers include CONNECT San Diego.